Neuro-oncologist Ingo K. Mellinghoff was appointed chair of the Department of Neurology at Memorial Sloan Kettering Cancer Center.
Beth Gaffney was named vice president of U.S. and Global Business Development at the National Clinical Trials Network.
The Reagan-Udall Foundation for the FDA has received $250,000 in funding from the Rockefeller Foundation to support the COVID-19 Diagnostics Evidence Accelerator launched earlier this year in collaboration with Friends of Cancer Research.
Global Cancer Institute has extended its programs to Bangladesh, with the launch of new monthly tumor boards that help physicians and oncologists in developing countries connect directly to U.S. physicians by videoconference to discuss challenging cancer cases and ask for advice.
Walter J. (Wally) Curran, Jr. said he would step down as executive director of Winship Cancer Institute of Emory University to serve as the global chief medical officer of GenesisCare, an international group described as “the world's largest provider of radiation oncology care and a major global provider of other medical services.”
Mark Bonnen was named chief medical officer at Mays Cancer Center at UT Health San Antonio.
Ben Ho Park, the Donna S. Hall Professor of Breast Cancer Research at Vanderbilt University Medical Center, was named director of the Division of Hematology and Oncology.
Michaela A. Dinan was named co-leader of the Cancer Prevention and Control Research Program at Yale Cancer Center, beginning Jan. 1, 2021.
A team of researchers from the University of Michigan Rogel Cancer Center received a $11.2 million grant from the National Heart, Lung and Blood Institute to study how to use the microbiome to limit complications of stem cell transplants for blood cancers and other diseases.
Yale Cancer Center member Sidi Chen, assistant professor of Genetics at Yale School of Medicine, and a member of the Yale West Campus Systems Biology Institute, was awarded a $500,000 research grant from Alliance for Cancer Gene Therapy to advance multiplexed activation of endogenous genes as an Immunotherapy or MAEGI technology.
